Tyrosine News and Research

RSS

Ubiquigent launches REDOXprofiler for rapid identification of REDOX cycling compounds

Ubiquigent Limited, a company specializing in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched REDOXprofiler.

24 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

In a new SLAS Discovery article, Helen Yu and a team of researchers at Gilead Sciences, Inc. present a time-resolved fluorescence resonance energy transfer-based Bruton's tyrosine kinase occupancy assay that can measure target engagement in peripheral blood mononuclear cells and in lymph-node and bone-marrow samples.

17 Jul 2018

Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer

Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib with T-DM1 against heavily pretreated HER2-positive breast cancer.

11 Jul 2018

Researchers discover mechanism that shuts down cell-to-cell communications pathway

Cellular functions rely on several communications networks that allow cells to rapidly respond to signals affecting the organism.

10 Jul 2018

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Through x-ray crystallography and kinase-inhibitor specificity profiling, University of California San Diego School of Medicine researchers, in collaboration with researchers at Peking University and Zhejiang University, reveal that curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 at the atomic level.

10 Jul 2018

Scientists create predictive model for neuroblastoma that incorporates early developmental signals

Neuroblastoma, a rare childhood cancer of the sympathetic nervous system, is particularly deadly because it is difficult to detect and thus generally advanced before treatment begins.

9 Jul 2018

Compounds found in green tea and red wine offer hope to treat inborn congenital metabolic diseases

A new Tel Aviv University study suggests there is hope of treating certain inborn congenital metabolic diseases -- a hope found in green tea and in red wine.

2 Jul 2018

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.

30 Jun 2018

Penn research team identifies novel therapeutic target for heart disease

Changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart muscle cells, and reversing these modifications can lessen the stiffness and improve the beating strength of these cells isolated from transplant patients with heart failure, found researchers from the Perelman School of Medicine at the University of Pennsylvania.

12 Jun 2018

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

In most of the Western World, cancer is the primary cause of death in children over the age of one. Existing treatments for adult cancer patients are not particularly effective for children.

31 May 2018

FDA-approved drug for lymphoma and leukemia may help treat common type of brain tumor

New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug for lymphoma and leukemia, may also help treat the most common – and deadliest – type of brain tumor.

30 May 2018

Two genes play vital roles in malignant brain cancer

Two genes play important roles for the formation of malignant cancer in the brain. One gene prevents the formation of the tumor, while another gene promotes the tumor. This is shown in a new dissertation at Umeå University, Sweden.

24 May 2018

Study provides insights into how immune cells kill bacteria with acid

The first line of immune defense against invading pathogens like bacteria are macrophages, immune cells that engulf every foreign object that crosses their way. After enclosing it in intracellular membrane vesicles, a process called phagocytosis, macrophages kill their prey with acid.

17 May 2018

Protein researchers identify several new potential targets for cancer

In a new study based on mouse cells internationally leading protein researchers have identified several new potential targets using state-of-the-art technology, many of which could be employed for future treatment of different types of cancers and diseases.

14 May 2018

Researchers recommend anti-cancer immunotherapies for treatment of thyroid cancer

University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers.

27 Apr 2018

Researchers discover new information related to rare form of leukemia

International research consortium led by researchers from the University of Helsinki, Finland, discovered new information related to a rare form of leukemia called aggressive NK-cell leukemia.

20 Apr 2018

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer.

18 Apr 2018

Study provides systematic view of gene enhancer activity in diverse tumors

At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.

5 Apr 2018

Salk scientists discover protein that 'turns off' uncontrolled liver cancer growth

Salk Institute scientists, together with researchers from Switzerland's University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer.

29 Mar 2018